Marco Bucci, PhD, Karolinska Institutet, Stockholm, Sweden, briefly describes the prognostic accuracy of tau positron emission tomography (PET) imaging for Alzheimer’s disease. The first tau-PET tracer was approved in 2020, a major development in the journey towards improved AD diagnosis. Research has indicated that tau-PET positivity is predictive for cognitive decline and may also predict amyloid positivity. It may therefore be able to provide a comprehensive AD diagnosis, without employing additional amyloid detection methodologies, although this requires further research. Crucially, Dr Bucci remarks that second generation tau-PET tracers are currently being studied for their diagnostic and prognostic value. This interview took place at the AP/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
